Motzer, R. J., Nosov, D., Eisen, T., Bondarenko, I., Lesovoy, V., Lipatov, O., . . . Hutson, T. E. (2013). Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. J Clin Oncol.
Chicago-стиль цитированияMotzer, Robert J., et al. "Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial." J Clin Oncol 2013.
MLA-цитированиеMotzer, Robert J., et al. "Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial." J Clin Oncol 2013.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.